A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials. The shot did not cause any serious side effects, according to a paper published on Thursday in the Journal of the American Medical Association (JAMA) by scientists who are part of Sinopharm and other China-based disease control authorities and research institutes.
In Indonesia, phase 3 clinical trial on coronavirus vaccine candidate CoronaVac has begun in Bandung, West Java, on Tuesday (11 August 2020) CoronaVac is developed by Chinese pharmaceutical giant Sinovac Biotech, who has selected its Indonesian counterpart Bio Farma to run the late-stage clinical trial at a facility belonging to Padjadjaran University's Faculty of Medicine. Bio Farma plans to produce 100 million doses of vaccine in August. They will also ramp up their production capacity up to 250 million vaccines by the end of this year.
CoronaVac is not Indonesia's only ray of hope for immunity against Covid-19 but we also have the Merah Putih (Red and White) vaccine which is named after the colors of the Indonesian flag. Red and White's development uses an isolated from the coronavirus that has been spreading in the country. The vaccine is likely to be ready by mid-2021.
There is also one key difference between CoronaVac and Red and White.
The former uses a single virus which will be multiplied in the lab and later separated prior to inactivation. By inactivating or killing off the virus, the vaccine candidate is safe for human use. In comparison, Red and White only take certain parts of the virus considered to be important to be multiplied and used as antigens.